Iparomlimab, a newly developed humanized anti-PD-1 checkpoint inhibitor, was tested as a monotherapy and demonstrated promising anti-tumor effects, with a clinically significant and durable response in the mCRC subset of patients, as well as an acceptable safety profile. The gene discussed is PDCD1; the disease is neoplasm.